PRAXIS PRECISION MEDICINES, INC. Research and Development Expense
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Research and Development Expense of $69.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. research and development expense for the quarter ending 2026-06-30 was $69.42M, a 10.17% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for the quarter ending 2026-03-31 was $77.99M, a 28.26% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for the quarter ending 2025-12-31 was $77.51M, a 37.70% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for the quarter ending 2025-09-30 was $65.80M, a 57.10% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for fiscal 2025 was $267.12M, a 75.26% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for fiscal 2024 was $152.41M, a 75.66% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for fiscal 2023 was $86.77M, a 44.04% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. research and development expense for fiscal 2022 was $155.04M, a 28.92% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.42M 10-Q · filed 2026-08-06 | $147.40M 10-Q · filed 2026-08-06 | $224.91M derived: sum of 3 quarters · filed 2026-08-06 | $290.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $77.99M 10-Q · filed 2026-05-07 | $155.49M derived: sum of 2 quarters · filed 2026-05-07 | $221.29M derived: sum of 3 quarters · filed 2026-05-07 | $284.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $77.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $143.30M derived: sum of 2 quarters · filed 2026-02-19 | $206.31M derived: sum of 3 quarters · filed 2026-08-06 | $267.12M 10-K · filed 2026-02-19 |
| 2025-09-30 | $65.80M 10-Q · filed 2025-11-05 | $128.80M derived: sum of 2 quarters · filed 2026-08-06 | $189.61M 10-Q · filed 2025-11-05 | $245.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $63.01M 10-Q · filed 2026-08-06 | $123.81M 10-Q · filed 2026-08-06 | $180.10M derived: sum of 3 quarters · filed 2026-08-06 | $221.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $60.81M 10-Q · filed 2026-05-07 | $117.09M derived: sum of 2 quarters · filed 2026-05-07 | $158.97M derived: sum of 3 quarters · filed 2026-05-07 | $186.24M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $56.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $98.17M derived: sum of 2 quarters · filed 2026-02-19 | $125.43M derived: sum of 3 quarters · filed 2026-02-19 | $152.41M 10-K · filed 2026-02-19 |
| 2024-09-30 | $41.88M 10-Q · filed 2025-11-05 | $69.14M derived: sum of 2 quarters · filed 2025-11-05 | $96.13M 10-Q · filed 2025-11-05 | $114.51M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $27.26M 10-Q · filed 2025-08-04 | $54.24M 10-Q · filed 2025-08-04 | $72.63M derived: sum of 3 quarters · filed 2026-02-19 | $89.89M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $26.98M 10-Q · filed 2025-05-02 | $45.37M derived: sum of 2 quarters · filed 2026-02-19 | $62.63M derived: sum of 3 quarters · filed 2026-02-19 | $88.25M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $35.65M derived: sum of 2 quarters · filed 2026-02-19 | $61.26M derived: sum of 3 quarters · filed 2026-02-19 | $86.77M 10-K · filed 2026-02-19 |
| 2023-09-30 | $17.26M 10-Q · filed 2024-11-06 | $42.87M derived: sum of 2 quarters · filed 2024-11-06 | $68.38M 10-Q · filed 2024-11-06 | $96.71M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $25.61M 10-Q · filed 2024-08-13 | $51.12M 10-Q · filed 2024-08-13 | $79.45M derived: sum of 3 quarters · filed 2024-08-13 | $109.89M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $25.50M 10-Q · filed 2024-05-13 | $53.83M derived: sum of 2 quarters · filed 2024-05-13 | $84.27M derived: sum of 3 quarters · filed 2024-05-13 | $127.89M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $28.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $58.77M derived: sum of 2 quarters · filed 2024-03-05 | $102.39M derived: sum of 3 quarters · filed 2024-03-05 | $155.04M 10-K · filed 2024-03-05 |
| 2022-09-30 | $30.44M 10-Q · filed 2023-11-07 | $74.06M derived: sum of 2 quarters · filed 2023-11-07 | $126.71M 10-Q · filed 2023-11-07 | $170.22M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $43.62M 10-Q · filed 2023-08-09 | $96.27M 10-Q · filed 2023-08-09 | $139.78M derived: sum of 3 quarters · filed 2023-08-09 | $172.92M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $52.65M 10-Q · filed 2023-05-11 | $96.16M derived: sum of 2 quarters · filed 2023-05-11 | $129.30M derived: sum of 3 quarters · filed 2023-05-11 | $154.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $43.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $76.65M derived: sum of 2 quarters · filed 2023-02-07 | $102.33M derived: sum of 3 quarters · filed 2023-02-07 | $120.26M 10-K · filed 2023-02-07 |
| 2021-09-30 | $33.14M 10-Q · filed 2022-11-09 | $58.82M derived: sum of 2 quarters · filed 2022-11-09 | $76.75M 10-Q · filed 2022-11-09 | $93.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $25.68M 10-Q · filed 2022-08-08 | $43.61M 10-Q · filed 2022-08-08 | $59.88M derived: sum of 3 quarters · filed 2022-08-08 | $72.67M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $17.93M 10-Q · filed 2022-05-09 | $34.20M derived: sum of 2 quarters · filed 2022-05-09 | $46.99M derived: sum of 3 quarters · filed 2022-05-09 | $56.04M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $16.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $29.06M derived: sum of 2 quarters · filed 2022-02-28 | $38.11M derived: sum of 3 quarters · filed 2022-02-28 | $44.98M 10-K · filed 2022-02-28 |
| 2020-09-30 | $12.79M 10-Q · filed 2021-11-03 | $21.84M derived: sum of 2 quarters · filed 2021-11-03 | $28.70M 10-Q · filed 2021-11-03 | $34.40M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $9.05M 10-Q · filed 2021-08-16 | $15.92M 10-Q · filed 2021-08-16 | $21.62M derived: sum of 3 quarters · filed 2021-08-16 | $30.96M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $6.87M 10-Q · filed 2021-05-11 | $12.57M derived: sum of 2 quarters · filed 2021-05-11 | $21.91M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $15.04M derived: sum of 2 quarters · filed 2021-03-17 | $29.56M 10-K · filed 2021-03-17 | |
| 2019-09-30 | $9.35M 10-Q · filed 2020-11-23 | $23.86M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |